ID   SCCT1
AC   CVCL_G307
SY   SCC T1
DR   cancercelllines; CVCL_G307
DR   Cosmic; 1608868
DR   Cosmic; 2688673
DR   GEO; GSM2611479
DR   GEO; GSM2611480
DR   GEO; GSM2611481
DR   Wikidata; Q54952396
RX   PubMed=21602893;
RX   PubMed=22006338;
RX   PubMed=24662767;
RX   PubMed=31336867;
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; c.1555+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly95Glu (c.284G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly115Ser (c.343G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Tyr577Ter (c.1731C>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly578Arg (c.1732G>C); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly578Ser (c.1732G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys861Tyr (c.2582G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Asp1515Glu (c.4545C>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Ser (c.701A>C); ClinVar=VCV000376690; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Forearm, skin; UBERON=UBERON_0003403.
ST   Source(s): PubMed=31336867
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 9,12
ST   D16S539: 12,13
ST   D18S51: 12,14
ST   D19S433: 14,15
ST   D21S11: 30,32.2
ST   D2S1338: 18,20
ST   D3S1358: 17
ST   D5S818: 12,13
ST   D7S820: 9,10
ST   D8S1179: 13
ST   FGA: 21,24
ST   TH01: 9,9.3
ST   TPOX: 9,12
ST   vWA: 14,16
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 10-09-24; Version: 15
//
RX   PubMed=21602893; DOI=10.1038/onc.2011.180; PMCID=PMC3219832;
RA   Watt S.A., Pourreyron C., Purdie K.J., Hogan C., Killick-Cole C.L.,
RA   Foster N., Pratt N., Bourdon J.-C., Appleyard M.V.C.L., Murray K.,
RA   Thompson A.M., Mao X., Mein C.A., Bruckner-Tuderman L.K., Evans A.,
RA   McGrath J.A., Proby C.M., Foerster J., Leigh I.M., South A.P.;
RT   "Integrative mRNA profiling comparing cultured primary cells with
RT   clinical samples reveals PLK1 and C20orf20 as therapeutic targets in
RT   cutaneous squamous cell carcinoma.";
RL   Oncogene 30:4666-4677(2011).
//
RX   PubMed=22006338; DOI=10.1073/pnas.1114669108; PMCID=PMC3203814;
RA   Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M.,
RA   Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L.R., Pennypacker S.,
RA   Zou Y., Sharma M., North J.P., Vemula S.S., Mauro T.M., Neuhaus I.M.,
RA   LeBoit P.E., Hur J.S., Park K., Huh N., Kwok P.-Y., Arron S.T.,
RA   Massion P.P., Bale A.E., Haussler D., Cleaver J.E., Gray J.W.,
RA   Spellman P.T., South A.P., Aster J.C., Blacklow S.C., Cho R.J.;
RT   "Loss-of-function mutations in Notch receptors in cutaneous and lung
RT   squamous cell carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17761-17766(2011).
//
RX   PubMed=24662767; DOI=10.1038/jid.2014.154; PMCID=PMC4753672;
RA   South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y.,
RA   Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., Xue D.J.,
RA   Dayal J.H.S., Robinson K.S., Rizvi S.M.H., Proby C.M., Harwood C.A.,
RA   Leigh I.M.;
RT   "NOTCH1 mutations occur early during cutaneous squamous cell
RT   carcinogenesis.";
RL   J. Invest. Dermatol. 134:2630-2638(2014).
//
RX   PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499;
RA   Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M.,
RA   Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D.,
RA   Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.;
RT   "A Unique panel of patient-derived cutaneous squamous cell carcinoma
RT   cell lines provides a preclinical pathway for therapeutic testing.";
RL   Int. J. Mol. Sci. 20:3428.1-3428.26(2019).
//